Comprehensive Pediatric Solid Tumor Panel
Use
The test is designed for individuals who exhibit features indicative of hereditary pediatric cancer syndromes, those with a cancer diagnosis within the first two decades of life, individuals with multiple primary cancers, or those with two or more affected family members who developed cancer before the age of 45. The panel aims to identify genetic mutations that may contribute to these cancer predisposition syndromes, providing valuable information for diagnosis, prognosis, and potential management strategies.
Special Instructions
STAT testing is available and incurs a 25% surcharge. Institutional pricing applies upon signing in. Orders can be placed online or via fax using the test requisition form. Included is the option for targeted family testing for additional analysis based on the initial report findings.
Limitations
This test has not been cleared or approved by the US Food and Drug Administration. The panel is based on NGS with CNV analysis, which may not detect all types of mutations. Variants of uncertain significance may be identified, requiring further clinical correlation. Exome-wide CNV analysis is not available for PG-Select panels, which includes this test.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7-16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided